NCT00952575View on ClinicalTrials.gov

Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Healthy
Interventions
DRUG

polyclonal anti-D immunoglobulin

single injection of 300 µg

DRUG

monoclonal anti-D immunoglobulin

Comparison of different dosages of LFB-R593

Trial Locations (1)

14050

Parexel Early Phase Clinical Unit, Berlin

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Laboratoire français de Fractionnement et de Biotechnologies

INDUSTRY